GleanMark

CTX320 Trademark

CTX320 is a USPTO trademark filed by CRISPR Therapeutics AG. Status: Registered.

Trademark Facts

MarkCTX320
Serial Number97461218
Registration Number8137672
StatusRegistered
Filing Date2022-06-16
Registration Date2026-02-10
Mark TypeWord
Nice Classes005 (Pharmaceuticals), 042 (Software & IT)
OwnerCRISPR Therapeutics AG
Attorney of RecordTiffany D. Gehrke
Prosecution Events54
Latest EventNRCC on 2026-02-10

Goods & Services

Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of cardiovascular diseases; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy

Recent Prosecution Activity

DateDocumentType
2026-02-10Notice of Registration EmailERO
2026-02-10Registration CertificateORC
2026-01-22Notice of Acceptance of SOU - EESO
2026-01-22TRAM Snapshot of App at Pub for OppostnPST
2026-01-06Amendment and Mail Process CompleteAMC
2026-01-05SpecimenSPE

USPTO Refusals on Record

Related